Hi Everyone! I want to know how to accurately code to avoid claims denials in Surgical Oncology Billing?
Great question, @AndrewBrains Here are the key CPT codes you need to know:
High-Use Surgical Oncology CPT Codes
-
19301/19302 Partial mastectomy (with/without lymph node removal).
-
38500/38525 Lymph node biopsy and dissection.
-
49203 49205 Excision of abdominal tumors.
-
32503/32504 Pulmonary resection with chest wall involvement.
To avoid claim denials, focus on three things:
-
Always pair procedure codes with accurate diagnosis (ICD-10) codes.
-
Document medical necessity clearly in operative notes.
-
Verify payer-specific bundling rules before submitting.
Proper modifier usage (like Modifier 22 for increased complexity) can also protect your reimbursement.
1 Like
Surgical Oncology CPT Codes That Actually Get Paid
Hey Andrew, welcome to the community! This is one of the most common pain points in oncology billing, so let’s break it down properly.
Why Claims Get Denied in the First Place
Most denials in surgical oncology aren’t random. They happen because:
-
The procedure code doesn’t match the documented diagnosis
-
Bundling rules weren’t checked before submission
-
Modifiers were missing or used incorrectly
Fix these three things and you’ll recover a significant chunk of rejected revenue almost immediately.
The CPT Codes You’ll Use Most
Breast Procedures
19301/19302 cover partial mastectomy, with 19302 including regional lymph node removal. Always confirm the operative note specifies what was actually removed.
Lymph Node Work
38500 to 38542 handle everything from open biopsy to radical dissection. The range matters, so code to the deepest level of dissection documented.
Abdominal Tumor Excision
49203 to 49205 are sized by tumor diameter. Your documentation needs to explicitly state the measurement or you’ll default to the lowest paying code automatically.
Thoracic Resections
32503/32504 apply when chest wall involvement is present. Without that documentation, you lose the additional reimbursement entirely.
Three Quick Wins to Reduce Denials Today
-
Audit your operative notes before billing, not after denial
-
Cross-check ICD-10 pairing for every oncology procedure code you submit
-
Apply Modifier 22 when procedures take significantly longer or are more complex than typical
Getting this right consistently is really a documentation problem more than a coding problem. When surgeons capture the right details, billing almost takes care of itself.
What specific procedure type is giving you the most trouble? Happy to go deeper on any of these.
This Oncology CPT Code guide might be helpful. Best of Luck!
1 Like
Really solid breakdown from both @HexaBillers11 and @StuartBrave. I want to add something that often gets overlooked in these conversations. 
Everyone talks about which CPT codes to use, and that is important, but the real denial risk in surgical oncology sits in how those codes are supported by documentation. 
You can code 49205 perfectly and still get denied because the operative note said “large mass” instead of actually measuring the tumor diameter. Payers will default you to 49203 every single time without that number written clearly.
Another thing worth flagging for anyone doing thoracic cases. 
The 32503 and 32504 codes require chest wall involvement to be explicitly documented, not just implied. Surgeons sometimes describe the procedure thoroughly but forget to state the clinical finding that justifies the higher code. That one omission costs real money.
On the modifier side, Modifier 22 is underused in surgical oncology. When a procedure runs significantly longer due to tumor complexity or prior treatment scarring, that needs to be captured in the operative note with specific language about time and difficulty. 
1 Like
Here is a reference table of commonly used Surgical Oncology CPT codes. These codes are frequently associated with tumor excisions, cancer resections, lymph node dissections, and oncologic surgeries across breast, gastrointestinal, hepatobiliary, pancreatic, and head & neck specialties.
| CPT Code | Procedure Description | Oncology Specialty |
|---|---|---|
| 19120 | Excision of breast lesion (benign or malignant) | Breast Oncology |
| 19125 | Excision of breast lesion identified by radiological marker | Breast Oncology |
| 19301 | Partial mastectomy (lumpectomy, segmentectomy) | Breast Surgical Oncology |
| 19303 | Simple/total mastectomy | Breast Surgical Oncology |
| 19307 | Modified radical mastectomy with axillary lymph node dissection | Breast Surgical Oncology |
| 38525 | Biopsy/excision of deep axillary lymph node(s) | Breast Oncology |
| 38745 | Axillary lymphadenectomy | Breast Oncology |
| 38747 | Retroperitoneal/abdominal lymph node dissection | GI & Urologic Oncology |
| 44140 | Partial colectomy with anastomosis | Colorectal Oncology |
| 44160 | Colectomy with terminal ileum removal | Colorectal Oncology |
| 45110 | Abdominoperineal resection (APR) | Colorectal Oncology |
| 47120 | Partial hepatectomy (liver resection) | Hepatobiliary Oncology |
| 47122 | Liver trisegmentectomy | Hepatobiliary Oncology |
| 47125 | Left hepatic lobectomy | Hepatobiliary Oncology |
| 47130 | Right hepatic lobectomy | Hepatobiliary Oncology |
| 48140 | Distal pancreatectomy | Pancreatic Oncology |
| 48150 | Whipple procedure (pancreaticoduodenectomy) | Pancreatic Oncology |
| 48153 | Pylorus-preserving Whipple procedure | Pancreatic Oncology |
| 49203 | Excision of intra-abdominal tumor ≤ 5 cm | Surgical Oncology |
| 49204 | Excision of intra-abdominal tumor 5–10 cm | Surgical Oncology |
| 49205 | Excision of intra-abdominal tumor > 10 cm | Surgical Oncology |
| 21044 | Excision of malignant mandibular tumor | Head & Neck Oncology |
| 21045 | Radical resection of malignant mandibular tumor | Head & Neck Oncology |
| 21555 | Excision of soft tissue tumor, neck/anterior thorax | Sarcoma Oncology |
| 21557 | Radical resection of soft tissue tumor (<5 cm) | Sarcoma Oncology |
| 21558 | Radical resection of soft tissue tumor (≥5 cm) | Sarcoma Oncology |
| 15732 | Myocutaneous/fasciocutaneous flap reconstruction | Head & Neck Oncology |
| 15756 | Free flap reconstruction with microvascular transfer | Reconstructive Oncology |
| 20969 | Free osteocutaneous flap with microvascular anastomosis | Head & Neck Oncology |
**
Data collected from the following resource:**
Great reference table from @Bestbillers and solid practical points from the earlier replies. I want to push back on something though, because I think this conversation, like most surgical oncology billing discussions, is missing the elephant in the room.
Everyone here is focused on which CPT codes to use and how to document them correctly. Fair enough. But the real denial problem in surgical oncology is not documentation gaps. It is that a significant portion of these codes were designed for fee-for-service incentives that actively reward procedural volume over outcomes, and payers know it. The reason denials on codes like 49205 or the Whipple (48150) are climbing is not because coders are making mistakes. It is because commercial payers have quietly started applying informal scrutiny thresholds on high-RVU oncology procedures that are not published anywhere in their coverage policies. You will not find it in the LCD. You will just see the denial.
On the practical side, a few things the thread has not covered:
Modifier 58 vs. 79 trips up a lot of surgical oncology teams. If a second procedure during the global period was planned and staged, that is Modifier 58. If it was unrelated to the original procedure, it is 79. Getting this backwards on cancer resection cases draws audit flags fast, especially when the second procedure involves lymph node dissection that arguably should have been bundled with the primary resection.
NCCI edits on reconstructive add-ons are another area worth flagging. Codes like 15732 and 15756 (the flap reconstruction codes in Bestbillers’ table) are frequently bundled by payers even when they are legitimately separate operative sessions. The standard guidance is to unbundle with Modifier 59 or the more specific XS/XU modifiers, but some MACs are inconsistently applying this even with proper documentation. If you are doing head and neck oncology reconstruction billing and seeing higher-than-normal denial rates on the flap codes, that is likely why.
The uncomfortable truth is that Modifier 22, which Robin flagged as underused, is actually over-relied upon in some practices as a revenue recovery tool rather than a genuine complexity indicator. Coders are under real pressure to recover revenue on complex cases and Modifier 22 has become a default lever. That draws RAC attention, and it is part of why surgical oncology as a specialty has seen increased probe audits in the past two years. Using it correctly matters, but using it defensively on every difficult case is a liability.
Document well, code accurately, but also recognize that some of your denial volume is a payer behavior problem, not a coding problem. Those two require very different responses.